(AOF) – Implanet, a medical technology company specializing in spinal implants, today announces the signing of a distribution agreement for its Jazz range in China and a technological partnership with Sanyou Medical. In accordance with the partnership project communicated on June 29, 2022 and following the success of the fundraising carried out with the support of Sanyou Medical, the collaboration between the two groups is materializing with the signing of two agreements, the first commercial and the second technological. .
The commercial agreement signed relates to the distribution of Implanet’s Jazz platform by Sanyou Medical in China. It is the world’s largest market in volume for spine surgeries, with 15,000 pediatric scoliosis surgeries and 750,000 adult surgeries performed each year.
Implanet intends to benefit from Sanyou Medical’s leadership in its domestic market as the second largest Chinese manufacturer of medical devices for spine surgery to deploy its solutions there on a long-term basis. Implanet’s proprietary Jazz range is also in progress with the Chinese health authorities.
The technological alliance linking Implanet and Sanyou Medical will allow the synergy of the technological know-how and R&D of the two groups with the aim of accelerating their product innovation policy. Thus, this partnership aims at the joint development of a new and unprecedented European range of a hybrid fixation system, including the very latest advances and innovations in spinal surgery (deformity treatment system, minimally invasive range, robotics , artificial intelligence, etc.).
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.